A Phase 1 interventional study of PEG Interferon Alfa-2b and Acetaminophen in Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-07-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is an extension study to base study protocol C/I97-188 (MK-4031-006). Its primary purpose is to assess the safety and tolerability of extended administration of polyethylene glycol (PEG) interferon alfa-2b in participants with solid tumors.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 29 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen
Participants receive PEG interferon alfa-2b 1.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen
Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen
Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen
Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen
Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
Drug: PEG Interferon Alfa-2b · Drug: Acetaminophen
Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
Also known as: MK-4031, SCH 54031, PEG Intron®
Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
Also known as: Tylenol®
Number of Participants Who Experienced an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 42 Weeks
Number of Participants Who Discontinued Treatment Due to an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 40 Weeks
Best Objective Response
Best Objective Response data were based on World Health Organization (WHO) criteria and included four categories. Complete Response (CR) was the disappearance of all clinically detectable malignant disease. Partial Response (PR) was a decrease of ≥50% of the sum of products of largest perpendicular diameters of all bidimensionally measurable lesions; and a decrease of ≥50% in sum of largest diameters of all unidimensionally measure lesions. Stable Disease (SD) was a \<50% decrease or \<25% increase in sum of products of largest perpendicular diameters of all bidimensionally measurable lesions; or a \<50% decrease or \<25% increase in sum of diameters of all unidimensionally measurable lesions. In addition, no new lesions appeared. Progressive Disease (PD) was a ≥25% increase in size of at least one bidimensionally or unidimensionally measurable lesion or appearance of new lesion. Occurrence of pleural effusion or ascites was also considered PD if substantiated by positive cytology.
Time frame: Up to 40 Weeks
| Milestone | PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW) | PEG Interferon Alfa-2b 1.5 mcg/kg OW | PEG Interferon Alfa-2b 3 mcg/kg OW | PEG Interferon Alfa-2b 4.5 mcg/kg OW | PEG Interferon Alfa-2b 6 mcg/kg OW | PEG Interferon Alfa-2b 7.5 mcg/kg OW |
|---|---|---|---|---|---|---|
| Started | 1 | 2 | 2 | 2 | 11 | 11 |
| Completed | 0 | 1 | 1 | 1 | 5 | 0 |
| Not completed | 1 | 1 | 1 | 1 | 6 | 11 |
| Withdrew: Not in participant's best interest | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Disease progression | 1 | 1 | 1 | 1 | 5 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | PEG Interferon Alfa-2b 0.75 mcg/kg OW | PEG Interferon Alfa-2b 1.5 mcg/kg OW | PEG Interferon Alfa-2b 3 mcg/kg OW | PEG Interferon Alfa-2b 4.5 mcg/kg OW | PEG Interferon Alfa-2b 6 mcg/kg OW | PEG Interferon Alfa-2b 7.5 mcg/kg OW |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event | 1 | 2 | 1 | 2 | 11 | 11 |
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | PEG Interferon Alfa-2b 0.75 mcg/kg OW | PEG Interferon Alfa-2b 1.5 mcg/kg OW | PEG Interferon Alfa-2b 3 mcg/kg OW | PEG Interferon Alfa-2b 4.5 mcg/kg OW | PEG Interferon Alfa-2b 6 mcg/kg OW | PEG Interferon Alfa-2b 7.5 mcg/kg OW |
|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Treatment Due to an Adverse Event | 0 | 0 | 0 | 0 | 0 | 3 |
Best Objective Response data were based on World Health Organization (WHO) criteria and included four categories. Complete Response (CR) was the disappearance of all clinically detectable malignant disease. Partial Response (PR) was a decrease of ≥50% of the sum of products of largest perpendicular diameters of all bidimensionally measurable lesions; and a decrease of ≥50% in sum of largest diameters of all unidimensionally measure lesions. Stable Disease (SD) was a \<50% decrease or \<25% increase in sum of products of largest perpendicular diameters of all bidimensionally measurable lesions; or a \<50% decrease or \<25% increase in sum of diameters of all unidimensionally measurable lesions. In addition, no new lesions appeared. Progressive Disease (PD) was a ≥25% increase in size of at least one bidimensionally or unidimensionally measurable lesion or appearance of new lesion. Occurrence of pleural effusion or ascites was also considered PD if substantiated by positive cytology.
| Participants | PEG Interferon Alfa-2b 0.75 mcg/kg OW | PEG Interferon Alfa-2b 1.5 mcg/kg OW | PEG Interferon Alfa-2b 3 mcg/kg OW | PEG Interferon Alfa-2b 4.5 mcg/kg OW | PEG Interferon Alfa-2b 6 mcg/kg OW | PEG Interferon Alfa-2b 7.5 mcg/kg OW |
|---|---|---|---|---|---|---|
| Complete Response (CR) | 0 | 0 | 1 | 0 | 3 | 0 |
| Partial Response (PR) | 0 | 0 | 0 | 1 | 0 | 4 |
| Stable Disease (SD) | 1 | 2 | 0 | 0 | 6 | 4 |
| Progressive Disease (PD) | 0 | 0 | 0 | 1 | 1 | 2 |
| Not Evaluated | 0 | 0 | 1 | 0 | 1 | 1 |
Collected over Up to 42 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG Interferon Alfa-2b 0.75 mcg/kg OW | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| PEG Interferon Alfa-2b 1.5 mcg/kg OW | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| PEG Interferon Alfa-2b 3 mcg/kg OW | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| PEG Interferon Alfa-2b 4.5 mcg/kg OW | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| PEG Interferon Alfa-2b 6 mcg/kg OW | 1/11 (9.1%) | 1/11 (9.1%) | 11/11 (100%) |
| PEG Interferon Alfa-2b 7.5 mcg/kg OW | 0/11 (0%) | 3/11 (27.3%) | 11/11 (100%) |
| Event | PEG Interferon Alfa-2b 0.75 mcg/kg OW | PEG Interferon Alfa-2b 1.5 mcg/kg OW | PEG Interferon Alfa-2b 3 mcg/kg OW | PEG Interferon Alfa-2b 4.5 mcg/kg OW | PEG Interferon Alfa-2b 6 mcg/kg OW | PEG Interferon Alfa-2b 7.5 mcg/kg OW |
|---|---|---|---|---|---|---|
| ASTHENIAGeneral disorders | 0/1 | 1/2 | 0/2 | 0/2 | 0/11 | 0/11 |
| PAINGeneral disorders | 0/1 | 1/2 | 0/2 | 0/2 | 0/11 | 0/11 |
| CONFUSIONAL STATEPsychiatric disorders | 0/1 | 1/2 | 0/2 | 0/2 | 0/11 | 0/11 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/1 | 0/2 | 0/2 | 0/2 | 0/11 | 1/11 |
| PYREXIAGeneral disorders | 0/1 | 0/2 | 0/2 | 0/2 | 0/11 | 1/11 |
| PNEUMONIAInfections and infestations | 0/1 | 0/2 | 0/2 | 0/2 | 0/11 | 1/11 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/1 | 0/2 | 0/2 | 0/2 | 0/11 | 1/11 |
| JOINT SWELLINGMusculoskeletal and connective tissue disorders | 0/1 | 0/2 | 0/2 | 0/2 | 0/11 | 1/11 |
| CONVULSIONNervous system disorders | 0/1 | 0/2 | 0/2 | 0/2 | 1/11 | 0/11 |
| SYNCOPENervous system disorders | 0/1 | 0/2 | 0/2 | 0/2 | 1/11 | 0/11 |
| Event | PEG Interferon Alfa-2b 0.75 mcg/kg OW | PEG Interferon Alfa-2b 1.5 mcg/kg OW | PEG Interferon Alfa-2b 3 mcg/kg OW | PEG Interferon Alfa-2b 4.5 mcg/kg OW | PEG Interferon Alfa-2b 6 mcg/kg OW | PEG Interferon Alfa-2b 7.5 mcg/kg OW |
|---|---|---|---|---|---|---|
| ABDOMINAL PAINGastrointestinal disorders | 1/1 | 0/2 | 0/2 | 0/2 | 2/11 | 2/11 |
| ASCITESGastrointestinal disorders | 1/1 | 0/2 | 0/2 | 0/2 | 0/11 | 0/11 |
| DIARRHOEAGastrointestinal disorders | 1/1 | 1/2 | 0/2 | 0/2 | 3/11 | 2/11 |
| NAUSEAGastrointestinal disorders | 0/1 | 2/2 | 0/2 | 0/2 | 2/11 | 4/11 |
| CHILLSGeneral disorders | 0/1 | 2/2 | 1/2 | 1/2 | 1/11 | 1/11 |
| FATIGUEGeneral disorders | 0/1 | 2/2 | 0/2 | 1/2 | 6/11 | 3/11 |
| OEDEMA PERIPHERALGeneral disorders | 1/1 | 0/2 | 0/2 | 0/2 | 0/11 | 1/11 |
| PYREXIAGeneral disorders | 0/1 | 2/2 | 0/2 | 1/2 | 0/11 | 3/11 |
| ANOREXIAMetabolism and nutrition disorders | 1/1 | 1/2 | 0/2 | 0/2 | 2/11 | 0/11 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 1/1 | 0/2 | 0/2 | 0/2 | 0/11 | 1/11 |
| Age, Continuous(Years) | PEG Interferon Alfa-2b 0.75 mcg/kg OW | PEG Interferon Alfa-2b 1.5 mcg/kg OW | PEG Interferon Alfa-2b 3 mcg/kg OW | PEG Interferon Alfa-2b 4.5 mcg/kg OW | PEG Interferon Alfa-2b 6 mcg/kg OW | PEG Interferon Alfa-2b 7.5 mcg/kg OW | Total |
|---|---|---|---|---|---|---|---|
| Mean | 62.0 ± NA | 51.5 ± 14.8 | 52 ± 0.0 | 59.5 ± 10.6 | 55.4 ± 9.6 | 55.8 ± 10.7 | 55.6 ± 9.5 |
| Sex: Female, Male(Participants) | PEG Interferon Alfa-2b 0.75 mcg/kg OW | PEG Interferon Alfa-2b 1.5 mcg/kg OW | PEG Interferon Alfa-2b 3 mcg/kg OW | PEG Interferon Alfa-2b 4.5 mcg/kg OW | PEG Interferon Alfa-2b 6 mcg/kg OW | PEG Interferon Alfa-2b 7.5 mcg/kg OW | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 0 | 1 | 3 | 1 | 7 |
| Male | 0 | 1 | 2 | 1 | 8 | 10 | 22 |
No study locations are listed for this record.
Ran from Dec 1997 to primary completion in Mar 2001, 38 months.
Results were first posted in Jul 2019, 18 years 3 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 38 months is close to that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b